The manifestation of leprosy in humans is largely determined by host immunity to Mycobacterium leprae and is a model for immunoregulation in a human disease. However, animal models available for exploration of the leprosy spectrum are inadequate. This study explored M. leprae infection in mice deficient in inducible nitric oxide synthase, and this report describes elements resembling borderline tuberculoid leprosy in humans.
The manifestation of leprosy in humans is largely determined by host immunity to Mycobacterium leprae and is a model for immunoregulation in a human disease. However, animal models available for exploration of the leprosy spectrum are inadequate. This study explored M. leprae infection in mice deficient in inducible nitric oxide synthase, and this report describes elements resembling borderline tuberculoid leprosy in humans.
A major component of the antimicrobial repertoire of effector mechanisms of activated macrophages (M⌽) is the production of reactive nitrogen intermediates (RNI), chiefly nitric oxide, generated from L-arginine by a high-output, cytokineinducible isoform of the enzyme, inducible nitric oxide synthase (iNOS). In murine models, RNI have been shown to be necessary for the M⌽-mediated inhibition of tumor cells and a variety of extracellular and intracellular pathogens (6, 17) . Evidence that RNI play a key antimicrobial role in human M⌽ is less direct but is accumulating (21) .
The use of the competitive inhibitor of L-arginine, N G -monomethyl-L-arginine (L-NMA), as well as other inhibitors of iNOS, including aminoguanidine (AG), allowed in vitro demonstration that M⌽ RNI are important in the gamma interferon (IFN-␥)-activated M⌽ killing of Mycobacterium leprae (2) and M. tuberculosis (1, 8, 11) . The inclusion of L-NMA or AG in drinking water permitted in vivo demonstration of the role of RNI in host resistance to M. bovis BCG (15) and M. tuberculosis (7, 13) , respectively. Recently, gene knockout (KO) mice with a targeted disruption in the calmodulin binding site of the iNOS gene (iNOS KO mice) were developed which lack a functional iNOS (16) . These iNOS KO mice yielded IFN-␥-treated M⌽ incapable of coping with M. tuberculosis (1) . In vivo infection with virulent M. tuberculosis was greatly exacerbated in this and another strain of iNOS-deficient mice (1, 18) .
The present studies employed iNOS KO mice to explore further the role of RNI in host resistance to viable M. leprae freshly harvested from infected nu/nu mice (3). Figure 1 shows in vitro results obtained with B6 and iNOS KO peritoneal M⌽ where additional controls consisted of B6 M⌽ treated with the RNI inhibitors L-NMA and AG. Clearly, activated iNOS KO M⌽ or B6 M⌽ treated with L-NMA or AG failed to produce RNI and were unable to kill or inhibit M. leprae. Similar results were obtained with bone marrow-derived M⌽ (not shown).
Dietary inhibition of RNI production was not a feasible approach by which to study the role of this antimicrobial mechanism of resistance to leprosy in vivo because the protracted nature of the mouse footpad model for infection with M. leprae requires several months to demonstrate growth. Therefore, M. leprae infection was carried out with iNOS KO mice to determine if, as in the M. tuberculosis model, M⌽ inability to cope with M. leprae infection in vitro is also manifested in vivo by exacerbated infection. We employed the standard Shepard mouse footpad assay (20) , in which the number of acid-fast bacilli (AFB) peaks at 4 to 6 months, plateaus for several months, and then gradually falls off to the counting threshold. As shown in Fig. 2 , M. leprae growth followed this typical pattern in control B6 mice over 18 months. In iNOS KO mice, counts of AFB per footpad were generally higher at 3 and 6 months in one experiment and 11 months in a second experiment although statistical significance (Welch's t test) was reached only at the 3-month time point (P Ͻ 0.05). More noteworthy, considering the marked differences in granuloma formation and histopathological responses (see below), were the findings that the number of AFB per footpad fell off at the same rate and to the same level in KO mice as in controls.
Clearly, growth of M. leprae was not greatly exacerbated in iNOS KO mice. These results appear to contrast with findings obtained with experimental M. tuberculosis infections, in which the absence of RNI was linked with the inability of activated M⌽ to kill in vitro coupled with exacerbated growth of the tubercle bacillus and increased mouse mortality (1, 7, 8, 13, 18) . Our findings also contrast with reports in which iNOSdeficient mice not only controlled M. avium growth in vivo but also did so in vitro in activated M⌽ (4, 5, 12, 14) . Thus, although the present studies appear to underscore the important role of RNI in M⌽-mediated resistance to M. leprae, these findings also demonstrate that control of M. leprae infection in vivo can be maintained in the absence of this potent antimicrobial mechanism. An important alternative antimicrobial pathway to be considered is the production of reactive oxygen intermediates (ROI) by M⌽. We have shown, however, that M⌽ from iNOS KO mice are not deficient in the production of ROI (1) but, in the absence of RNI, ROI alone is not sufficient to kill either M. tuberculosis or M. leprae.
Control of M. leprae growth in iNOS-deficient mice may involve a more complicated compensatory consequence of the microenvironmental conditions associated with granuloma for-mation. At 15 months in B6 mice, the granuloma which formed around an injected bolus of M. leprae was confined to a small area in the footpad immediately underneath the epidermis (Fig. 3A) and consisted of small focal collections of M⌽, a few epithelioid cells, and lymphocytes which were collected around neurovascular bundles. The inflammation did not invade nerves or muscles. There were minimal superficial extensions along the tissue spaces between muscle bundles. Acidfast staining (not shown) revealed a few clumps of bacilli inside M⌽, especially in those found immediately beneath the epidermis. In marked contrast, the granulomatous inflammation of the iNOS KO footpad was over 10 times the size of the granuloma found in the control mice (Fig. 3B) . The granuloma was distributed over an area underneath the epidermis, around neurovascular bundles, and was spread along the tissue spaces between muscle bundles, even reaching the bones. The granuloma was confluent and organized and was composed of numerous epithelioid cells, a few M⌽, and dense collections of lymphocytes (Fig. 3C) . In areas, the granuloma infiltrated the muscle bundles, partly destroying them (Fig. 3D) , and also infiltrated the perineurium. Acid-fast staining (not shown) revealed clumps of bacilli inside M⌽ mainly in the middle of the granuloma. Thus, granuloma formation in iNOS KO mice was ultimately associated with destruction of M. leprae and persisting organisms continued to evoke a granulomatous response. Two recent studies (12, 14) have shown enhanced granuloma formation in M. avium-infected mice when production of RNI was inhibited by either gene disruption or chemical inhibition, and this response was attributed to modulation of cytokine production. Ongoing immunohistopathological studies and evaluation of local cytokine profiles in our M. leprae-infected mouse footpad model may shed further light on these compensatory mechanisms of resistance.
Finally, it is noteworthy that our findings appear to share attributes with an important form of human leprosy. Overall, the histological picture seen in iNOS KO mice was one resembling human borderline tuberculoid leprosy. The broad clinical-immunopathological spectrum of leprosy represents a fascinating example of immunoregulation in a chronic, nonfatal human infectious disease. But current murine models of experimental leprosy generally represent only the polar forms of the disease: tuberculoid leprosy with limited growth in the footpads of conventional, immunocompetent mice and lepromatous leprosy in which growth is largely unrestricted in the footpads of athymic nu/nu mice (9, 10). The borderline area of the clinical-immunopathological manifestations of leprosy is by far the most intriguing to immunologists. Unlike the tuberculoid and lepromatous forms, the borderline form is unstable and may downgrade and evolve into a more lepromatous disease or upgrade into a more tuberculoid disease, often with the appearance of a "reversal reaction" resulting from the onset of enhanced cell-mediated immunity with damaging consequences for surrounding nerves.
In humans, understanding the mechanisms and prevention of reversal reactions is one of the main goals of leprosy research. The development of strains of mice with targeted gene disruptions has opened up the possibility of exploring models more representative of the human leprosy spectrum. As the M. leprae-infected footpad lesions of iNOS KO mice appear to resemble borderline tuberculoid lesions, the present findings may be exploitable as a model for understanding the instability of borderline disease. Experiments are under way to determine the host response to larger numbers of M. leprae organisms and explore the possibility of further manipulation of the cell-mediated immune system in infected iNOS KO mice. 
